SPONSORS
Engage a community ready to support the development of Psychedelic Medicine
Event Partners
Short Wave Pharma
Shortwave presents an IP-driven, biotechnologically focused approach to the development of regulatorily-feasible formulations and delivery methods of psychedelics based medicine, addressed at unmet critical needs of patients suffering from mental health disorders, neurodegenerative diseases and chronic pain. Shortwave’s initial program focuses on treatment-resistant anorexia nervosa, an area with high mortality and morbidity, recognized by the FDA as an acute unmet need eligible for treatment by psychedelics.
Cybin Inc.
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.
Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
Negev Capital
Negev Capital is a psychedelic medical intervention investment fund with assets of USD$30+ million. The Company invests in drug discovery, with a focus on preclinical and/or Phase 1 stages of development. They aim to support those early-stage companies in need of capital that promote the thoughtful, responsible, medical use of psychedelic medication for psychiatric disorders, and who have excellent management and science teams, and solid IP.
COMPASS
At COMPASS, our vision is a world of mental wellbeing. Every one of us is committed to discovering and developing new therapies that will help patients and their families. For too many people, mental health care today isn’t good enough. We are determined to change that.
Our first major initiative is developing COMP360 psilocybin therapy through late-stage clinical trials in Europe and North America for people with treatment-resistant depression. Read more about our science.
Clerkenwell Health
From Phase I to III, Clerkenwell Health can support drug manufacturers at every point of their clinical development journey, right through to market approval.
Launched in early 2021, Clerkenwell Health provides strategic guidance on the optimal research methodologies, including advice on drug tapering and selection of outcome measures to maximise trial impact and high-value data output.
FTI Consulting
FTI Consulting has built an unrivalled, global strategic communications offering to life science and healthcare companies. Our global team has the breadth and depth of experience in pharmaceuticals, biotech, medical devices, digital health and healthcare services to help clients share the right message to the right audience at the right time.
We design and execute communication programmes to protect and promote reputation, enhance stakeholder engagement and build a premium valuation.
BEAUTIFUL SPACE
Beautiful Space is Europes leading innovation in psychedelic-assisted couples therapy. Operating as a safe and legal commercial company in the UK and the Netherlands they have generated media interest by addressing the problem in relationships and sexual intimacy with their unique program of relationship wellness
Their official collaboration with Imperial College London will recruit 20 couples later this year.
PSYCH Symposium: London 2022 was a sold-out event, with key partners promoting access to psychedelic healthcare in Europe. With over 60% of attendees in C-suite positions, PSYCH connects organisations with qualified professionals to support the discovery, development and delivery of psychedelic medicine
To build upon this momentum, PSYCH Symposium returns to London, at the iconic British Museum, in July 2023. To partner with PSYCH at the landmark event, please register your interest below.
25K
MEDIA SUBSCRIBERS
25,000 investors, academics, researchers and drug developers receive the latest psychedelic healthcare news each week in The Psychedelics Newsletter.
350
QUALIFIED ATTENDEES
At the sold out inaugural event, 60% of attendees were either C-suite or senior management level. The symposium was also attended virtually by 250 virtual delegates, generating over 1 million social media impressions.
55%
EUROPEAN AUDIENCE
The majority of attendees at PSYCH Symposium: London 2022 were from Europe, with 30% from the pharmaceutical industry and one in six working in finance.
“PSYCH HAS DEVELOPED A LEADER POSITION IN THE PSYCHEDELIC HEALTHCARE INDUSTRY. WE ARE THRILLED TO PARTNER ON THE SYMPOSIUM AND FUTURE EVENTS.”
BENJAMIN LIGHTBURN
CHIEF EXECUTIVE OFFICER, FILAMENT HEALTH
“PSYCH SYMPOSIUM WAS A GREAT PLACE FOR MINDMED TO PROVIDE SPONSORSHIP. THE SPEAKERS ARE THE LEADERS IN THE FIELD, PROGRESSING THE INDUSTRY.”
DANIEL KARLIN
CHIEF MEDICAL OFFICER, MINDMED
“WE’D RATE THE SPONSORSHIP OF THE PSYCH SYMPOSIUM AS FIVE OUT OF FIVE, AND LOOK FORWARD TO PARTNERING ON FUTURE EVENTS.”
KEN BELOTSKY
PARTNER, NEGEV CAPITAL
